Pseudomonas aeruginosa is a versatile opportunistic pathogen causing a wide variety of hospital-acquired acute infections in immunocompromised patients as well as chronic respiratory infections in patients suffering from cystic fibrosis or other chronic respiratory diseases. Several traits contribute to its ability to colonize and persist in the lungs of chronically infected patients, including development of high resistance to antimicrobials and hypermutability, biofilm growth, and alginate hyperproduction, or a customized pathogenicity, which may include the loss of classical virulence factors and metabolic changes. Here we argue that a combination of both intrinsic and environmental mutagenesis leads to a high number of mutant variants in the population. The conducive environment then triggers a positive feedback loop leading to adaptation and persistence of P. aeruginosa, rendering these chronic infections almost impossible to eradicate.
Pseudomonas aeruginosa is an opportunistic pathogen involved in chronic respiratory and hospital-acquired infections [1] . In cystic fibrosis (CF) patients, this bacterium causes chronic lung infections that result in significant morbidity and mortality [2] . This bacterium possesses several traits that contribute to its ability to colonize and persist in respiratory infections, including a plethora of regulatory mechanisms that enable it to coordinate metabolic pathways and optimize nutritional and reproductive potential [1] . By analyzing all the mutagenesis sources affecting the P. aeruginosa genome, we conclude in this review that the mutation rate of the whole population may be extremely high. This fact, together with the special conditions of the chronically infected respiratory tract, engenders a positive feedback loop leading to adaptation and persistence of P. aeruginosa in the lungs of CF patients and evolving to intractable infections.
MANY PHENOTYPIC VARIANTS EXIST IN CHRONIC LUNG INFECTIONS
In chronic respiratory infections involving repeated medical interventions and new colonization events, bacterial communities evolve over time, leading to a set of variants with niche specialists and increased antimicrobial resistance and persistence [3] . It is clear that the properties of bacterial cells that are present late in P. aeruginosa infections of CF airways differ greatly from the properties of cells that start the infection many years before the decline in lung function becomes life threatening [3] . This diversification appears to ensure the persistence of the infection. The phenotypic variants described in the scientific literature include the following. Variants that cause overproduction of the exopolysaccharide alginate. The well-described mucoid phenotype is a hallmark of the CF chronic infection. The genetic mechanisms underlying the switch to mucoidity in P. aeruginosa have been well studied and mainly consist of mutational inactivation of the mucA gene [4] . Because mucoid P. aeruginosa variants are rarely isolated from other infections or environments, there is a clear association with obstructive diseases that provide better conditions to select for overproduction of exopolysaccharides, such as CF, bronchiestasis, and chronic obstructive pulmonary disease [5] . Although this variant is very successful, the most common situation should be the coexistence of mucoid and nonmucoid strains in the respiratory tract but with different zonal distribution [6] . Small colony variants (SCVs) characterized by their reduced colony size (1-3 mm) in agar-based culture media and associated with increased antimicrobial resistance, notably to aminoglycosides, and poorer lung function in CF patients [7] . A frequent subgroup of SCVs isolated from CF patients is hyperpiliated and shows autoaggregative properties, increased twitching motility, strong adherence to pneumocytic cells, and high biofilm formation capacity [8] . SCVs, like mucoid variants, are therefore thought to notably contribute to the persistence of the chronic colonization. Variants with resistance to multiple antimicrobial agents driven by mutations determining the alteration of the targets, permeability (porins) deficiencies, hyperproduction of chromosomal b-lactamases, or overexpression of efflux systems [9] . Variants characterized by the presence of auxotrophic mutants of P. aeruginosa in chronic infections. Auxotrophs are dependent upon specific amino acids or vitamins for growth. The exacerbation of chronic symptoms in CF patients is associated with an increase in the auxotrophic population [10] . Variants with deficiency in the flagellation. This has been observed in CF patients in poor clinical condition. Nonmotile bacteria expressing neither flagellin nor pilin are frequently recovered from chronically colonized CF patients. These strains, probably generated by mutations in rpoN or genes for flagellum synthesis, are resistant to macrophage engulfment [11] . Variants characterized by increased spontaneous mutation rates. These strains are frequently found in the lungs of CF patients [12] . These variants are extremely prevalent in chronic infections, in contrast to what has been described in acute infections [13] , suggesting that hypermutation is important in bacterial adaptation for long-term persistence [14] . Furthermore, hypermutation plays a key role in the development of multiple-antimicrobial resistance [15, 16] . Variants with loss of a quorum sensing (QS) system. This is common in CF isolates [3] . It has been proposed that lasR mutants, defective in QS, occur as an adaptation to chronic infections. The presence of lasR mutants can be an indication that QS is not an important factor in the clinical strain's ability to maintain the infection [17] , particularly in the late stages. Variants with changes in the type III protein secretion system, an important virulence factor. Following P. aeruginosa infection of CF patient airways, there is a gradual loss of proteins due to mutation from the type III secretion system that may be very frequent among CF isolated strains [18] . Variants that produce pyomelanin. Recently we have determined that the mutational inactivation of the hmgA gene may be the main factor responsible for this phenotype. Pyomelanin-producing strains are better adapted to chronic infection in a murine model of chronic lung infection, although with reduced virulence [19] .
It is important to point out that different mutations leading to adaptive changes can be present in the same strain at the same time [3] . Because mutagenesis is the reason for the phenotypic variation and adaptation of P. aeruginosa to the environment of the lungs in chronic respiratory diseases, we shall now discuss the origin of mutations in this environment.
MULTIPLE MUTATION SOURCES CAUSE PHENOTYPIC DIVERSITY IN CHRONIC P. AERUGINOSA INFECTIONS
Is the chronically infected lung a mutagenic context? All evidence points to the affirmative. In the origin of mutations and mutants, intrinsic and extrinsic factors are involved, acting alone or in union, raising or triggering the emergence of phenotypic variations. Here we discuss those factors, their contributions, and their possible interactions.
Extrinsic Factors That Promote Mutagenesis
It is well established that environmental conditions have a strong influence on the spontaneous mutation rate of bacteria. For instance, a 10-fold change can be achieved only by changing the nutritional composition of the media [20] .
The altered level of reactive oxygen species (ROS) that originates in the respiratory tract of chronically infected patients mainly comes from polymorphonuclear leukocyte action [21] . ROS generation is not exclusive to immune or epithelial cells but can be enhanced by the imbalance of iron homeostasis in patients suffering from CF and chronic obstructive pulmonary diseases [22] . At the same time, the increased bioavailability of iron can be used for bacterial growth and replication, resulting in more virulent and persistent infections [23] . Moreover, the antioxidant mechanisms in CF patients are highly diminished. For example, levels of glutathione, the most significant component of the antioxidant lung defenses, are very low [24] . Once antioxidant protection is overwhelmed, ROS can further increase the inflammatory responses and thus contribute significantly to the vicious cycle of inflammation so familiar in CF [25] . ROS can then stimulate persistence of infections and enhance the capability of bacteria to evolve new variants because reactive oxygen radicals are involved in DNA damage and mutation in bacteria [21] .
Antibiotics are continuously used in chronic lung infections. At sublethal concentrations, they may stimulate bacterial mutation and recombination, consequently promoting bacterial adaptation to different types of stress, including antibiotic pressure [26] [27] [28] [29] . Therefore, regions exposed to subinhibitory concentrations may become antibiotic-induced mutation hotspots responsible, at least in part, for phenotypic variation and specifically for the emergence and maintenance of hypermutable and mucoid strains.
Mutations Depend on Intrinsic Factors
Those intrinsic factors rely mainly on the bacterial DNA replication and fidelity maintenance machinery. For example, hypermutable strains of P. aeruginosa are frequently isolated from the lungs of CF patients [12, 15, 21] . The main cause of hypermutation in naturally occurring P. aeruginosa strains is the inactivation of the mismatch repair system. The antimutator genes mutS, mutL, and uvrD are the most frequently affected [12, 15] . Isolates with nonmutator, weak, or strong mutator phenotypes are found at all time points, showing coexistence of these subpopulations. This suggests a parallel evolution in the different focal niches of infection in the CF lung. Defects in other antimutator genes (mutT, mutM, and mutY) have also been involved in the generation of mutator strains [30] . Mutators can increase in frequency, even when their initial population size is very small, probably because several beneficial mutations are required for adaptation. The hypermutable phenotype may be advantageous in fluctuating environments [31] , probably explaining why hypermutation is a relevant factor in the development of multiple-antimicrobial resistance in P. aeruginosa strains causing chronic lung infections [15, 16] . Thus, the genetic processes leading to the bacterial phenotypic variability in the airways of CF patients may be catalyzed by stable hypermutation [3, 14, 32] .
The SOS system may play an underappreciated role in the response to several commonly used antibiotics [33] . There is some evidence that error-prone replication by the Y family of DNA polymerases contributes significantly to mutagenesis [33] . In P. aeruginosa, the SOS response appears to have retained control over induced mutation. Thus, it seems likely that the initial reduction in metabolism observed in P. aeruginosa provides time for the SOS response to produce mutations that allow the cell to persist and eventually to evolve resistance [33] .
Biofilm Contributes to Mutagenesis and Persistence
Another source of genetic variability might be the biofilm mode of growth. During the chronic phase of lung infection of CF patients, P. aeruginosa readily forms the characteristic communities of cells encased in an extracellular matrix consisting of secreted proteins, polysaccharides, nucleic acids, and cellular debris and attached to surfaces. Most researchers agree on the great importance that biofilm plays in the pathogenesis of chronic respiratory infection, considering it an essential step in the progress of the diseases. The conversion of P. aeruginosa to mucoidy phenotype greatly favors biofilm formation [2] .
Adaptive mutation may also play a major role in biofilm development and evolution. It has been demonstrated that P. aeruginosa undergoes extensive genetic diversification during short-term growth in biofilm communities in a way that is similar to the genetic variations of chronic lung infections [34] .
The mutability may be increased when bacteria grows in biofilm. One study showed that when P. aeruginosa grows in biofilms, 4 genes encoding antioxidant enzymes (katA, sodB, ahpC, and PA3529) are downregulated, decreasing protection against oxidative mutagenesis. The frequency of rifampicin-and ciprofloxacin-resistant mutants increased 15-fold and 105-fold, respectively, in P. aeruginosa PAO1 biofilm [35] . In the same line, Boles and Singh [36] demonstrated that double-strand break mutations are more frequent in biofilm than in planktonic cultures, increasing the diversity by mutation. Moreover, heterogeneous microenvironments exist within biofilms due to oxygen and nutrient diffusional limitations [37] . In the CF lung, P. aeruginosa biofilms are poorly penetrated by ROS [38] , limiting bacterial mortality from host-produced radicals. However, the more superficial layers may be the substrate of the ROS-induced mutations. The same principle applies to many antibiotics, as subinhibitory antibiotic concentrations during treatments can promote mutagenesis and increase resistance [26] [27] [28] [29] 39] .
A great number of phenotypic variants are, however, defective in biofilm formation. For example, the study of CF isolates showed that biofilm formation followed a trend of decreased adherence with the progression of chronic lung infection, suggesting that at these stages nonmucoid P. aeruginosa survives [40] . In other words, lung deterioration creates an environment where bacteria can be present beyond biofilm growth.
The physical and chemical properties (viscosity and density) of respiratory secretions provide a medium of special characteristics in CF lungs [41] . In these patients a depletion of the periciliary liquid layer occurs, which can decrease both mucociliary and cough transportability. Perez-Vilar and Boucher [42] proposed that mucus dehydration produces increased mucin concentration, decreased mucin pH, and alteration of reduced glutathione and myeloperoxidase levels. This leads to the formation of additional inter-chain mucin bonds and these extra cross-links increase viscoelasticity, leading to poor mucus clearance [42] . Thus, it can be hypothesized that airway secretions can provide a gel substrate where bacteria can grow and may be protected from host defenses and probably from antibiotic therapy. Can bacteria growing in this condition be considered as biofilm? It is such a particular environment that a definitive definition is difficult to give. The protection of bacteria can be explained because the high molecular overcrowding may impede or decrease the diffusion processes of antibiotics and host defense effectors like antibodies and complement elements.
In biofilms, the same principle may apply for ROS, where highly viscous secretions can act as a shield, protecting bacteria from reactive species or decreasing ROS activity to subinhibitory but mutagenic concentrations. Then, in general terms, the rule appears to be that bacteria grow both in biofilm and planktonically, with mucoid and nonmucoid strains and mutator and nonmutator variants, probably with some temporal and spatial compartmentalization that may depend on the evolution of the diseases but always involve mutagenesis processes.
We have reviewed the main extrinsic and intrinsic causes of bacterial mutation in chronic respiratory infections caused by P. aeruginosa. Most studies focus their attention on a particular mutation mechanism leading to persistence and antibiotic resistance. Nevertheless, the most common situation might be the concomitant action of some or all these mutational paths together, acting synergistically to produce a larger number and greater diversity of mutations than previously estimated. There is evidence showing that such a synergistic action is possible. Treatment of some mutator strains with H 2 O 2 caused a huge increase in mutant frequency, only explained by a synergistic effect of oxidation-mediated mutagenesis and the high mutation rate of a specific hypermutable genetic background [43] . Also, subinhibitory concentrations of antibiotics can further increase the mutation rate of mutator strains [28] . Thus, the mutation rate of the P. aeruginosa population in chronically infected CF lungs is likely underestimated. The concerted action of all mutation sources may raise the population mutation rate to levels never seen before in naturally occurring populations of bacteria. It should be noted here that hypermutation is thought to be disadvantageous for the long term. However, this disadvantage can be buffered in permissive environments.
CHRONICALLY INFECTED AIRWAYS ARE PERMISSIVE ENVIRONMENTS FOR P. AERUGINOSA MUTANT VARIANTS
A bacterial population entering a region that offers a wide variety of untapped ecological opportunities, like a CF lung, would experience an explosive radiation of specialized types (Figure 1) .
In the previous sections, we have discussed the positive effects of mutagenesis to the adaptation of P. aeruginosa to the respiratory tract in chronic infections. We have proposed that the high mutation rate of the whole population, contributed by both intrinsic and environmental factors, allows the P. aeruginosa genome to explore new phenotypes. However, it has been proposed that hypermutation has a cost in the course of long-term evolution because of the accumulation of deleterious mutations. The effects of these deleterious mutations have been studied in laboratory models and in free living conditions but not in the environment of the CF lung, and in such environments fitness cost comes into question.
The balance between deleterious and advantageous mutations is altered in the chronically infected lung environment because of the survival of a great number of mutants, which does not occur in other environments. These mutants do not have a significant disadvantage under the prevalent conditions of the CF inflamed lung tissues, where cellular lysis may provide access to a wide range of nutrients available to bacteria, including high concentrations of amino acids and iron [10] . Among such abundance, the loss of biosynthetic pathways might be an advantage, ensuring a higher cellular economy and the possibility of outcompeting prototrophic strains. Moreover, the loss of other systems, such as motility-related-genes (accounting for about 5% of the genome) [44] , QS signaling, and targets of antibiotics, does not compromise the fitness of P. aeruginosa in the chronically infected lung environment. Therefore, the deteriorated lungs of CF patients can be considered a permissive environment for many P. aeruginosa variants (doomed to extinction in a nonpermissive environment). As a result, P. aeruginosa populations can exist in the CF lung as a cloud of closely related variants with multiple mutations, where each variant contributes to the fitness of the population [45] . In contrast, the CF lung can also be considered an exigent environment, where bacteria must survive to some still active immune system response elements or hard antibiotic treatments.
SPECULATIVE DIGRESSION
The high phenotypic variability generated during the process brings to mind, to some extent, the viral quasispecies model, where viruses compete within a highly mutagenic environment [46] . The quasispecies theory explicitly incorporates mutationselection balance in a large number of loci and is often used to describe the dynamics of species with relatively high mutation rates and large population sizes. In this view, populations consist of a ''cloud'' of genotypes dispersed in sequence space, possibly clustered around one or a few best adapted types [46] . The 2 main cornerstones of the quasispecies model, a high mutation rate on average and a large population size, can be found in P. aeruginosa chronic lung infections, where the bacterial load can be as high as 10 8 -10
9 bacteria per milliliter of respiratory secretion [47] . Another relevant feature of the model is the very heterogeneous genetic population, which is also a characteristic of this infective process. The existence of quasispecies has been shown in a number of viruses, such as human immunodeficiency virus type 1, hepatitis C virus, and foot-andmouth disease virus. In addition, it has been proposed that it might be applicable to other biological systems that can fit with the essential requirements [46] . For example, it has been proposed that Helicobacter pylori, which persists chronically within individuals, generates populations of closely related but different bacteria that behave like a quasispecies [48] . In lungs chronically infected by P. aeruginosa, both mutation rates and population sizes can be even higher.
CONCLUSIONS AND FUTURE PROSPECTS
To summarize, the special CF lung environment (both permissive and stimulating at the same time), including antibiotic intervention [26] , may accelerate adaptation by the generation of mutant variants, including mutators that can additionally increase adaptation, producing niche specialists [3, 12] and antibiotic-resistant strains [15] . This scenario, with biofilms that protect bacteria and provide the genetic reservoir, has the potential to generate as much diversity as needed. The bacterial load is so high that it allows great plasticity to the population. All these processes occur while the lungs deteriorate. Once the chronic phase is well established, it is possible to slow the evolution of the infection but not to stop it, ending with a fatal outcome for the patient. The picture is a positive feedback loop triggered by mutagenesis ( Figure 1 ) and maintained by the permissive but stimulating environment, which makes the infection virtually impossible to eradicate. From the medical point of view, outstanding progress has been made in the treatment of CF patients through the use of aggressive antimicrobial treatments that have prolonged the life expectancy of patients [2] . However, the very deep nature of the genetic, physiological, and ecological bases of the P. aeruginosa chronic infection should be understood to find new intervention strategies. For instance, the interaction among different sources of mutation, including environmental ROS and the frequently found hypermutable strains, remains obscure and deserves additional investigation. The contribution of subinhibitory antibiotic levels and their interaction with reactive oxygen species and other mutagenesis sources, like SOS-induced mutagenesis or biofilm state, also needs to be understood.
Interestingly, Bull and Wilke [49] have recently suggested that bacteria might be candidates for lethal mutagenesis (ie, bacterial populations with high mutation rates can be driven to extinction by artificially raising the mutation rate to the point that deleterious load causes the extinction of the population [error catastrophe]). It is tempting to speculate that this is similar to what has been proposed for RNA viruses and that populations of P. aeruginosa in chronic infections are ideal candidates for this approach. However, the singular nature of the P. aeruginosa chronic lung infection, including the high permissiveness of this particular environment together with the absence of safe drugs that specifically increase the mutation rate, makes this approach unrealistic at this time. Perhaps the opposite approachddiminishing the mutation rate to a minimum to impede adaptability and the evolution of antibiotic resistancedcould be more feasible. The possibility that components of induced mutation pathways might be inhibited as a therapeutic strategy to prevent the development of antibiotic resistance has been proposed. Studies by Romesberg and coworkers [33, 50] have shown that prevention of SOS activation resulted in a decrease of bacterial mutagenesis, avoiding the development of antibiotic resistance in antibiotic-treated infected mice.
A rational approach to combat the appearance and selection of hypermutable P. aeruginosa populations is the use of combined antibiotic therapy, because the mutation rate necessary to reach resistance to 2 or more antibiotics simultaneously is unattainable even for hypermutators [9] . Nevertheless, although Figure 1 . Endogenous and exogenous factors affecting the total number of mutations available for the whole population (mutation supply) of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. A higher mutation supply provides more opportunities for adaptation (adaptive changes). Adapted mutants start new cycles of mutagenesis and selection of new adaptations in a self-sustained vicious circle, leading to increasing difficulty in treating chronic disease. ROS, reactive oxygen species.
combined antibiotic therapy is a common practice with CF patients, hypermutable and antibiotic resistant strains are still isolated. This situation led us to speculate that there are hidden elements in the equation. The interaction of all mutagenic pathways discussed here may produce an unexpectedly high mutation rate, overcoming the probabilistic threshold imposed by the intrinsic spontaneous mutagenesis of P. aeruginosa.
Notes

